Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADX-2191 in Retinitis Pigmentosa
NCT05392179Phase 2Completed
- Sponsor
- Aldeyra Therapeutics
- Start
- Jul 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ADX-2191 in retinitis pigmentosa (RP) (2 arms), sponsored by Aldeyra Therapeutics. Primary endpoint: Serious Adverse Events at 16 weeks. Started Jul 2022; status: completed.
02
Drugs
ADX-2191
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on NCT05392179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05392179.